Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

COVID-19 4Neoplasms 2Severe Acute Respiratory Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis 1Lymphoma 1Leukemia, Myeloid, Acute 1Hypersensitivity 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1

Interventions

Standard of Care 8Hydroxychloroquine 4BNT162 Vaccine 4Practice Guidelines as Topic 3Blood Specimen Collection 32019-nCoV Vaccine mRNA-1273 3tocilizumab 2sotrovimab 2cilgavimab and tixagevimab drug combination 2Specimen Handling 2Sodium Chloride 2CVnCoV COVID-19 vaccine 2COVID-19 Vaccines 2COH04S1 COVID-19 vaccine 2Azithromycin 2sinovac COVID-19 vaccine 1selinexor 1remdesivir 1proxalutamide 1palbociclib 1ogalvibart 1monalizumab 1lenzilumab 1crexavibart 1ciclesonide 1bemcentinib 1avdoralimab 1acalabrutinib 1XAV-19 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × COVID-19 × BNT162 Vaccine × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

NCT05016622 2024-07-31

Booster Dose Trial

Montefiore Medical Center

Phase 2 Terminated
106 enrolled 39 charts

COVID-19, Neoplasms

NCT05075538 2024-01-17

I-SPARC

Jules Bordet Institute

Phase 4 Terminated
152 enrolled

COVID-19, Neoplasms

NCT04951323 2022-05-18

Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)

University of Liege

Phase 3 Unknown
50 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡